Core Viewpoint - The company Beishimei (300796) expects a significant increase in net profit for the first half of 2025, driven by product optimization and successful international trade channel development [1] Financial Performance - The projected net profit attributable to shareholders for January 1 to June 30, 2025, is estimated to be between 33.11 million yuan and 44.42 million yuan, compared to 16.55 million yuan in the same period last year, representing a year-on-year growth of 100.07% to 168.38% [1] - The expected net profit after deducting non-recurring gains and losses is forecasted to be between 29.87 million yuan and 41.18 million yuan, up from 14.55 million yuan in the previous year, indicating a growth of 105.33% to 183.05% [1] Drivers of Growth - The growth in performance is primarily attributed to the optimization of product structure, the successful introduction of new products, and the effective establishment of international trade channels [1] - There has been a significant increase in profits from trade-related products, and the gross profit margin for the fundraising project "8500 tons of ketone series green new materials" has turned positive [1]

Group 1: Company Overview and Strategic Projects - Shaoxing Bestmay Chemical Co., Ltd. is actively expanding its product lines in the C5 chemical sector, including the "Annual Production of 8,500 Tons of Ketone Series Green New Materials Project" and the "Annual Production of 12,100 Tons of Cyclopentane Series Green New Materials Project" [1][2][3] - The company has achieved stable operation of its ketone facility, with product quality meeting standards and sales status being steady [2][3] - The company is positioned as a leader in the domestic C5 comprehensive utilization field, enhancing its product offerings and reducing reliance on imports [2][3] Group 2: Financial Performance and Growth - In 2024, the company reported a revenue of 1.328 billion RMB, representing a year-on-year growth of 89.97% due to the full-year consolidation of Ningbo Jielike's operations following an 80% stake acquisition [5][6] - The revenue from C5 series products increased from 11.67 million RMB in 2023 to 73.12 million RMB in 2024, marking a growth of 5.26 times [20] Group 3: Research and Development - The company invested 45.52 million RMB in R&D in 2024, a 13.7% increase from the previous year, and holds 58 authorized patents, including 32 invention patents [6][8] - The focus on R&D has led to the development of proprietary technologies that enhance production efficiency and reduce costs, such as low-temperature continuous nitration and solid salt recovery technologies [18] Group 4: Market Position and Competitive Advantage - The company is recognized as a national high-tech enterprise and has established a complete production and R&D capability for the herbicide Dimethenamid-P, covering the entire industry chain from intermediates to formulations [8][15] - The company has a strong export presence, with its subsidiary Jielike operating in 79 countries, achieving over 75% of its revenue from overseas markets in 2024 [15][19] Group 5: Future Outlook and Strategic Initiatives - The company plans to continue focusing on environmentally friendly pesticide development and expand its C5 new materials product line to enhance market share and profitability [5][15] - The company aims to leverage its existing market channels and the acquisition of Jielike to penetrate emerging markets in South America, Africa, and Southeast Asia, thereby increasing sales of Dimethenamid-P [11][15]